FDA approves oral dermatomyositis therapy - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

  • By

  • Kathryn Wighton

  • August 28, 2026

  • 2 min

Share

Original Source(s)

FDA approves oral dermatomyositis therapy

  • by Kathryn Wighton

  • August 28, 2026

Related Content

Editorial: Rethinking infection in pediatric atopic dermatitis: from microbial dysbiosis to precision prevention

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

Development of Arthritis in a Large Real-World Cohort of Patients With Pediatric Onset Psoriasis